AMR Clinical Trials

9 recruitingLast updated: May 13, 2026

There are 9 actively recruiting amr clinical trials across 11 countries. Studies span Phase 2, Not Applicable, Phase 3. Top locations include At-Bashy Village, Naryn Region, Kyrgyzstan, Atlanta, Georgia, United States, Barcelona, Spain. Updated daily from ClinicalTrials.gov.


AMR Trials at a Glance

9 actively recruiting trials for amr are listed on ClinicalTrialsFinder across 6 cities in 11 countries. The largest study group is Phase 2 with 3 trials, with the heaviest enrollment activity in At-Bashy Village, Atlanta, and Barcelona. Lead sponsors running amr studies include Guohui Xu, IRCCS Azienda Ospedaliero-Universitaria di Bologna, and Alexion Pharmaceuticals, Inc..

Browse amr trials by phase

Treatments under study

About AMR Clinical Trials

Looking for clinical trials for AMR? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new AMR trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about AMR clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting
Phase 2

Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation

Kidney TransplantationAMRAntibody-mediated Rejection+1 more
Alexion Pharmaceuticals, Inc.45 enrolled55 locationsNCT06744647
Recruiting
Phase 3

TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma

Unresectable Hepatocellular CarcinomaApatinibCamrelizumab+1 more
Guohui Xu101 enrolled1 locationNCT06485466
Recruiting
Not Applicable

CRP and Patient Information Leaflets to Optimise Antibiotic Treatments for Adults With Respiratory Tract Infections in Primary Care in Kyrgyzstan

InflammationRespiratory Tract Infection BacterialRespiratory Tract Infection Viral+2 more
Rigshospitalet, Denmark1,050 enrolled2 locationsNCT07261969
Recruiting

PK/PD Relationship of CAZ/AVI and FOS in the Treatment of Patients With Infections Due to CRE

Antimicrobial Resistance (AMR)Gram-negative Infections
IRCCS Azienda Ospedaliero-Universitaria di Bologna60 enrolled2 locationsNCT06717594
Recruiting
Phase 2

Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma

MelanomaAcral MelanomaNeoadjuvant+4 more
Peking University Cancer Hospital & Institute60 enrolled1 locationNCT05512481
Recruiting

NCCR AntiResist:: New Approaches to Combat Antibiotic-resistant Bacteria

Antimicrobial Resistance (AMR)
University Hospital, Basel, Switzerland8,000 enrolled1 locationNCT05017766
Recruiting
Phase 2

Clinical Study of Camrelizumab Combined With TCb Versus TCb in Neoadjuvant Treatment of Triple-negative Breast Cancer

Breast CancerTriple-Negative Breast CancerCamrelizumab
Zhenzhen Liu369 enrolled1 locationNCT05475678
Recruiting

PK/PD Analysis of Ceftazidime/Avibactam or Cefiderocol With or Without Fosfomycin for the Treatment of Difficult To-treat Gram-negative Infections

Antimicrobial Resistance (AMR)Gram Negative Infection
University of Bologna120 enrolled11 locationsNCT06651047
Recruiting
Not Applicable

bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC

Hepatocellular CarcinomaImmunotherapyCamrelizumab+2 more
Sun Yat-sen University40 enrolled1 locationNCT06061276